COLESEVELAM HYDROCHLORIDE

Colesevelam hydrochloride, commonly known by the brand name Welchol, is a medication that has been extensively studied in clinical trials for various conditions. This drug belongs to a class called bile acid sequestrants, which work by binding to bile acids in the intestine and preventing their reabsorption. Originally approved for lowering LDL cholesterol, clinical research has expanded to investigate its effects on glucose metabolism, diabetes management, and other conditions. This article provides an overview of how colesevelam hydrochloride has been used in clinical trials, its effectiveness for different conditions, and what patients might expect when taking this medication.

Table of Contents

What is Colesevelam Hydrochloride?

Colesevelam hydrochloride (also known by brand names Welchol, Cholestagel, or Lodalis) is a medication that belongs to a class of drugs called bile acid sequestrants. It was initially approved by the U.S. Food and Drug Administration (FDA) in 2000 for treating high cholesterol levels and later received approval for improving blood sugar control in patients with type 2 diabetes mellitus[1].

Unlike many other medications, colesevelam is non-absorbable, meaning it is not taken up by the body into the bloodstream. Instead, it works within the digestive tract to bind to substances called bile acids[2]. This unique mechanism gives colesevelam a favorable safety profile since it doesn’t enter the bloodstream.

How Colesevelam Works

Colesevelam works through a process called bile acid sequestration. When you eat, your liver releases bile acids into your intestines to help digest fats. Normally, most bile acids are reabsorbed by the body after digestion. Colesevelam binds to these bile acids in the intestine, preventing their reabsorption, and the bound bile acids are eliminated from the body in the stool[3].

This process has two important effects:

  1. Cholesterol reduction: When bile acids are removed from the body, the liver needs to make more bile acids to replace them. To do this, the liver uses cholesterol, which helps lower cholesterol levels in the blood. Additionally, the liver increases the number of LDL receptors on its surface, which helps remove more LDL (“bad”) cholesterol from the bloodstream[4].
  2. Blood glucose improvement: The exact mechanism for how colesevelam improves blood sugar control isn’t fully understood. Research suggests it may involve changes in glucose metabolism in the liver, improved insulin sensitivity, and effects on hormones called incretins that help regulate blood sugar[5].

Medical Uses

High Cholesterol Management

Colesevelam is approved for lowering LDL (low-density lipoprotein) cholesterol, commonly known as “bad cholesterol.” It can be used:

  • As a primary therapy in adults with primary hyperlipidemia (elevated cholesterol levels)
  • In combination with statins (another type of cholesterol-lowering medication) when statins alone don’t adequately control cholesterol levels
  • For treating heterozygous familial hypercholesterolemia (an inherited condition causing high cholesterol) in pediatric patients 10-17 years old[4]

Clinical trials have shown that colesevelam can reduce LDL cholesterol by approximately 15-18% when used alone and can provide additional 8-16% reduction when added to statin therapy[6].

Type 2 Diabetes Management

Colesevelam is also approved for improving glycemic (blood sugar) control in adults with type 2 diabetes mellitus. It can be used in combination with other diabetes medications such as metformin, sulfonylureas, or insulin[7].

In clinical studies, adding colesevelam to existing diabetes therapy reduced hemoglobin A1c (HbA1c, a measure of long-term blood sugar control) by approximately 0.5% compared to placebo. This improvement was seen within 4-6 weeks of starting treatment and reached maximum effect after 12-18 weeks[8].

Research suggests that colesevelam’s blood sugar-lowering effect may involve multiple mechanisms:

  • Reduced hepatic (liver) glucose production
  • Improved insulin sensitivity
  • Effects on incretin hormones like GLP-1 (glucagon-like peptide-1)
  • Changes in bile acid signaling pathways that affect metabolism[2]

Type 1 Diabetes

While colesevelam is not currently approved for type 1 diabetes, research has investigated its potential benefits in this population. One study examined whether colesevelam could reduce LDL cholesterol in patients with type 1 diabetes while also potentially providing glycemic benefits[9].

This research aimed to demonstrate a 10% LDL reduction in type 1 diabetic patients with initial LDL levels above 100 mg/dL after twelve weeks of treatment. The study also evaluated effects on glucose control through HbA1c measurements and continuous glucose monitoring[9].

Bile Acid Disorders

Although not an FDA-approved indication, colesevelam has been studied for treating conditions related to bile acid dysfunction:

  • Bile Acid Diarrhea (BAD): This condition occurs when excess bile acids reach the colon, causing diarrhea. Research shows colesevelam may effectively bind these excess bile acids and reduce diarrhea symptoms[10].
  • Irritable Bowel Syndrome with Diarrhea (IBS-D): Some patients with IBS-D may have underlying bile acid malabsorption. Studies have examined whether colesevelam can improve symptoms by binding excess bile acids in these patients[11].
  • Cholestatic Pruritus: This is intense itching caused by liver diseases that affect bile flow. Bile acid sequestrants like colesevelam may help relieve itching by binding bile acids that build up in the skin[12].

Other Potential Uses

Research is exploring additional potential uses for colesevelam:

  • Nonalcoholic Steatohepatitis (NASH): This is liver inflammation and damage caused by fat buildup. Research is investigating whether colesevelam could help reduce liver fat and inflammation in NASH patients[13].
  • Prediabetes: Studies have examined whether colesevelam might help people with impaired fasting glucose (prediabetes) by improving insulin sensitivity and β-cell function[5].
  • Cancer Treatment-Related Diarrhea: One study explored whether colesevelam could help manage diarrhea associated with lenalidomide, a medication used to treat multiple myeloma[14].

Dosage and Administration

Colesevelam is available in two forms:

  • Tablets: 625 mg tablets
  • Powder for oral suspension: Packets that contain the medication in powder form to be mixed with water or other liquids

The typical adult dosage varies depending on the condition being treated:

  • For high cholesterol: 3.75 grams daily, taken as 6 tablets once daily or 3 tablets twice daily with meals
  • For type 2 diabetes: The same 3.75 grams daily dosage
  • For pediatric patients with familial hypercholesterolemia: Dosing is based on weight and age, typically starting with a lower dose of 1.875 grams daily and potentially increasing to 3.75 grams daily[15]

Important administration guidelines include:

  • Take with meals and plenty of water
  • If you’re taking other medications, take them at least 4 hours before colesevelam to prevent interference with absorption
  • If using the powder form, mix it thoroughly with water or other liquids according to the instructions
  • Do not take in dry form – always mix the powder with liquid

Side Effects and Safety

Because colesevelam is not absorbed into the bloodstream, it generally has fewer systemic side effects compared to many other medications. The most common side effects include:

  • Gastrointestinal issues: Constipation, indigestion, nausea, bloating
  • Increased triglycerides: In some patients, especially those with already elevated triglyceride levels
  • Vitamin deficiencies: Long-term use may affect absorption of fat-soluble vitamins (A, D, E, and K)[16]

Serious side effects are rare but may include:

  • Severe constipation
  • Bowel obstruction (especially in patients with existing gastrointestinal disorders)
  • Significant triglyceride elevation (which could potentially lead to pancreatitis in susceptible individuals)

Colesevelam should be used with caution in patients with:

  • Triglyceride levels above 300 mg/dL
  • History of pancreatitis due to hypertriglyceridemia
  • Gastroparesis (delayed stomach emptying)
  • History of bowel obstruction or major gastrointestinal surgery
  • Difficulty swallowing

Compared to older bile acid sequestrants like cholestyramine, colesevelam is generally better tolerated. A study using the Bile Acid Sequestrant Acceptability (BASA) scale found that patients rated colesevelam more favorably than cholestyramine, particularly regarding taste and texture[17].

Ongoing Research

Research continues to explore new applications and mechanisms of action for colesevelam. Some areas of current investigation include:

  • Bile acid signaling: Studies are investigating how bile acids act as signaling molecules that affect metabolism and how colesevelam might modify these effects[1].
  • Incretin effects: Research is examining how colesevelam affects gut hormones like GLP-1 that help regulate blood sugar and appetite[18].
  • Combinations with newer diabetes medications: Studies are looking at how colesevelam works when combined with newer diabetes medications like SGLT2 inhibitors or DPP-4 inhibitors[19].
  • Effects after bariatric surgery: Research is investigating how colesevelam might affect the altered bile acid metabolism that occurs after weight loss surgery[20].

Conclusion

Colesevelam hydrochloride represents an important medication option for patients managing high cholesterol and type 2 diabetes. Its unique mechanism of action – binding bile acids in the digestive tract – allows it to lower cholesterol and improve blood sugar control simultaneously, making it particularly valuable for patients with both conditions. The medication’s safety profile, with minimal systemic absorption, makes it suitable for many patients who may not tolerate other treatments.

While primarily approved for cholesterol management and type 2 diabetes, ongoing research continues to explore additional applications for colesevelam in conditions ranging from bile acid diarrhea to nonalcoholic steatohepatitis. As with any medication, patients should work closely with their healthcare providers to determine if colesevelam is appropriate for their specific health needs and to monitor for potential side effects.

Aspect Details
Primary Uses in Clinical Trials – Lowering LDL cholesterol in hypercholesterolemia
– Improving glycemic control in type 2 diabetes
– Managing bile acid diarrhea and IBS-D
– Treating prediabetes (impaired fasting glucose)
– Investigating effects in type 1 diabetes
Mechanism of Action – Binds bile acids in intestine, preventing reabsorption
– Reduces hepatic cholesterol, increasing LDL receptor activity
– May improve insulin sensitivity and glucose metabolism
– May influence incretin hormone production (GLP-1, GIP)
Dosage in Clinical Trials – Adults: Typically 3.75 g daily (six 625 mg tablets)
– Pediatric: Low dose (1.875 g) and high dose (3.75 g) studied
– Usually administered with meals
– Available as tablets or powder for oral suspension
Clinical Efficacy – Reduced LDL cholesterol by approximately 10-15%
– Lowered HbA1c by 0.4-0.5% in type 2 diabetes
– Improved symptoms in bile acid diarrhea (reduced stool frequency and improved consistency)
– Showed benefits for fasting glucose and postprandial glucose levels
Side Effects Observed – Gastrointestinal effects: constipation, flatulence, abdominal pain
– Generally well-tolerated compared to other bile acid sequestrants
– Low systemic absorption reduces risk of systemic side effects
– Potential for drug interactions due to binding mechanism
Special Populations Studied – Pediatric patients with familial hypercholesterolemia
– Pediatric patients with type 2 diabetes
– Patients with bile acid malabsorption
– Patients with prediabetes (impaired fasting glucose)
– Patients with irritable bowel syndrome with diarrhea
Combination Therapies – Added to metformin for diabetes management
– Combined with sulfonylureas
– Used with insulin therapy
– Combined with statins for enhanced cholesterol lowering
– Studied with sitagliptin for potential synergistic effects on glucose control

Ongoing Clinical Trials on COLESEVELAM HYDROCHLORIDE

  • Study on the Effectiveness and Safety of Colesevelam Hydrochloride for Patients with Idiopathic Bile Acid Diarrhea (BAD)

    Recruiting

    Investigated drugs:
    Belgium Denmark Italy Romania Spain
  • Study of the effectiveness and safety of colesevelam hydrochloride for patients with moderate-to-severe bile acid diarrhoea.

    Not yet recruiting

    1 1
    Italy

Glossary

  • Bile Acid Sequestrant: A class of medications that bind to bile acids in the intestine, preventing their reabsorption. This leads to increased excretion of bile acids and can result in lowered cholesterol levels.
  • HbA1c (Glycosylated Hemoglobin): A blood test that measures the average blood glucose levels over the previous 2-3 months. It's used to diagnose diabetes and monitor how well diabetes is being controlled.
  • LDL Cholesterol: Low-density lipoprotein cholesterol, often called 'bad cholesterol,' can build up in arteries and increase risk of heart disease.
  • Type 2 Diabetes Mellitus: A chronic condition affecting how the body processes blood sugar (glucose), characterized by insulin resistance and/or insufficient insulin production.
  • Impaired Glucose Tolerance: A pre-diabetic state where blood glucose levels are higher than normal but not high enough to be classified as diabetes.
  • Continuous Glucose Monitoring (CGM): A method to track glucose levels throughout the day and night using a sensor inserted under the skin that transmits readings to a recording device.
  • Insulin Sensitivity: A measure of how responsive body tissues are to insulin. Higher insulin sensitivity means the body uses insulin more effectively.
  • Endogenous Glucose Production (EGP): The amount of glucose produced by the liver, primarily through processes like gluconeogenesis and glycogenolysis.
  • Gluconeogenesis: A metabolic pathway that results in the generation of glucose from non-carbohydrate carbon sources, such as lactate, glycerol, and amino acids.
  • Glycogenolysis: The breakdown of glycogen to glucose, which occurs primarily in the liver and muscles.
  • Bile Acid Malabsorption (BAM): A condition where bile acids are not properly reabsorbed in the intestine, leading to increased concentration in the colon which can cause diarrhea.
  • Nonalcoholic Steatohepatitis (NASH): A type of liver disease characterized by inflammation and fat accumulation in the liver, not caused by alcohol consumption.
  • Irritable Bowel Syndrome with Diarrhea (IBS-D): A functional gastrointestinal disorder characterized by abdominal pain and altered bowel habits, primarily diarrhea.
  • Disposition Index: A measure of beta-cell function in relation to insulin sensitivity, used to assess the risk of developing diabetes.
  • Incretin Hormones: Hormones produced by the intestine in response to food that stimulate insulin secretion, including GLP-1 and GIP.
  • GLP-1 (Glucagon-like Peptide-1): A hormone that stimulates insulin secretion and inhibits glucagon release, helping to lower blood glucose levels.
  • GIP (Glucose-dependent Insulinotropic Peptide): An incretin hormone that stimulates insulin secretion in response to elevated blood glucose levels.
  • HOMA-IR: Homeostatic Model Assessment of Insulin Resistance, a method used to quantify insulin resistance and beta-cell function.
  • Bristol Stool Form Scale: A medical tool used to classify the form of human feces into seven categories, used in assessing digestive disorders.
  • SeHCAT Test: A nuclear medicine test used to diagnose bile acid malabsorption by measuring retention of a radioactive bile acid analog.

References

  1. https://clinicaltrials.gov/study/NCT00476710
  2. https://clinicaltrials.gov/study/NCT00596427
  3. https://clinicaltrials.gov/study/NCT00570739
  4. https://clinicaltrials.gov/study/NCT00145574
  5. https://clinicaltrials.gov/study/NCT00990184
  6. https://clinicaltrials.gov/study/NCT00185107
  7. https://clinicaltrials.gov/study/NCT00147719
  8. https://clinicaltrials.gov/study/NCT00151749
  9. https://clinicaltrials.gov/study/NCT00938405
  10. https://clinicaltrials.gov/study/NCT03876717
  11. https://clinicaltrials.gov/study/NCT00911612
  12. https://clinicaltrials.gov/study/NCT00756171
  13. https://clinicaltrials.gov/study/NCT01066364
  14. https://clinicaltrials.gov/study/NCT03767257
  15. https://clinicaltrials.gov/study/NCT01258075
  16. https://clinicaltrials.gov/study/NCT00753779
  17. https://clinicaltrials.gov/study/NCT01122108
  18. https://clinicaltrials.gov/study/NCT01092663
  19. https://clinicaltrials.gov/study/NCT02682680
  20. https://clinicaltrials.gov/study/NCT06925997